Novo Nordisk Launches New Treatment for Diabetes in Singapore
New innovation by Novo Nordisk combines two distinct insulin analogues, insulin degludec and insulin aspart in the ratio of 70 percent and 30 percent, that maintains stable control of glucose levels...